Orphan diseases are rare disorders that affect less than one in 2000 people in Canada or less than 200,000 individuals in the United States. But, collectively, the 7000 knownorphan diseases impact 1 in 12 Canadians, causing physical and mental hardship, and draining money and resources from our health care system.
The $4.9-million, Genome Canada-funded IGNITE project (Orphan Diseases: Identifying Genes and Novel Therapeutics to Enhance Treatment) is designed to help alleviate the impacts of orphan diseases, and provide new solutions for the patients, families and caregivers of this diverse range of human diseases.
The IGNITE project is focused on helping those with orphan diseases. It is designed to address the issue from a variety of angles, and has five clear goals:
Genome Atlantic gratefully acknowledges the financial support of the Government of Canada through Genome Canada, as well as the Atlantic Canada Opportunities Agency and the provincial governments of Newfoundland and Labrador, Nova Scotia, New Brunswick, and Prince Edward Island.
Genome Atlantic is one of 7 Genome Centres in Canada that are part of the Genome Canada Enterprise. This network encourages collaboration, with each centre focusing on the needs of their respective regions.
Site Navigation
WE FOCUS ON CLIENT LED SOLUTIONS.
BRING US AND IDEA AND WE’LL HELP YOU GET IT INTO ACTION.
WE FOCUS ON CLIENT LED SOLUTIONS.
BRING US AND IDEA AND WE’LL HELP YOU GET IT INTO ACTION.
